Tiny Mitochondrial Peptide MOTS-c Shields Retinal Blood Vessels From Diabetes Damage

Diabetic retinopathy remains one of the most feared complications of diabetes, a progressive disease of the tiny blood vessels that nourish the retina and the leading cause of blindness in working-age adults worldwide. Current treatments, ranging from laser therapy to injections of anti-VEGF drugs, largely target advanced disease, leaving clinicians with few options for patients in the early stages, when the damage is still reversible. A new study published in Cell Death Discovery by Yinglin Liao, Jinjin Xiang and colleagues at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School of Nanjing University, and collaborating institutions now points to an unexpected guardian of the retinal vasculature: a small peptide encoded not in the nuclear genome, but in the DNA of mitochondria, the energy-producing organelles inside our cells.

The peptide, known as MOTS-c, is transcribed from the mitochondrial open-reading-frame of the 12S rRNA-c region. Since its discovery, MOTS-c has attracted intense interest as one of a handful of mitochondrial-derived peptides that can act as signaling molecules, influencing metabolism, stress responses and aging far beyond the organelle where they are made. What the Nanjing-led team has done is to trace its role in the eye with unusual precision. Using retinal tissue, they showed that MOTS-c is predominantly localized in retinal endothelial cells, the thin, tightly connected cells that form the inner lining of blood vessels and constitute the blood-retinal barrier, the critical interface that keeps the light-sensitive tissue protected and properly nourished.

That localization matters because the earliest events in diabetic retinopathy are vascular. Chronically high blood sugar injures endothelial cells, weakens the junctions between them, and allows fluid and blood components to leak into the retina. It also damages mitochondria within the endothelial cells themselves, promoting the accumulation of reactive lipid peroxides that attack cellular membranes. To test whether MOTS-c is a casualty of this process, the researchers exposed human retinal endothelial cells to high glucose concentrations and studied a streptozotocin-induced diabetic mouse model, a standard experimental system in which the drug destroys insulin-producing cells and produces sustained hyperglycemia. In both settings, high glucose reduced the expression of MOTS-c in the retinal vasculature, suggesting that the loss of this mitochondrial signal is part of the injury program that diabetes unleashes on the eye.

The therapeutic logic followed directly. When the team supplied MOTS-c to human retinal endothelial cells suffering high-glucose-induced injury, the peptide protected the endothelial barrier and ameliorated mitochondrial dysfunction. The same benefit appeared in the diabetic mice: MOTS-c treatment rescued vascular endothelial damage in the retina. These genetic and pharmacological approaches, applied both in cell culture and in living animals, established that the peptide’s dysregulation is not merely a byproduct of disease but a mechanistically meaningful contributor to the vascular breakdown that drives diabetic retinopathy.

The deeper question was how a 16-amino-acid peptide could accomplish this. To find out, the researchers turned to unbiased molecular profiling. Transcriptomic analyses, which survey changes in gene expression across the whole genome, and lipidomic analyses, which map the constellation of fats and phospholipids inside the cells, converged on a surprising pathway: MOTS-c increased the activity of phospholipase A2, a family of enzymes that cleave phospholipids, the molecules that form the backbone of every cellular membrane, and thereby regulated phospholipid metabolism. In other words, the mitochondrial peptide appears to reprogram how endothelial cells maintain and remodel their own membranes under diabetic stress.

Among the differentially expressed genes associated with this upregulated phospholipase A2 activity, one stood out. Phospholipase A2 group VI, known as PLA2G6, showed the most significant upregulation following MOTS-c treatment. PLA2G6, an intracellular calcium-independent phospholipase, is best known in other contexts for its role in lipid homeostasis and, when mutated, in neurodegenerative disease. In the diabetic retina, the new work assigns it a protective job: PLA2G6-mediated degradation of lipid peroxides served as a primary mediator of the endothelial barrier protection seen during MOTS-c treatment. Lipid peroxides are the corrosive products of unsaturated fatty acid oxidation, and their accumulation is a hallmark of ferroptosis and related forms of oxidative cell death. By accelerating their breakdown, PLA2G6 effectively detoxifies the membrane environment of stressed endothelial cells.

The causal chain was then tested in the most demanding way, by removing the link. When the researchers knocked down PLA2G6, the protective effect of MOTS-c against vascular endothelial damage collapsed, both in vitro and in vivo. The peptide could no longer defend the endothelial barrier without its enzymatic partner. This loss-of-function result elevates the finding from correlation to mechanism: MOTS-c acts upstream, PLA2G6 acts downstream, and the degradation of lipid peroxides is the functional bridge between them. It also suggests that patients or experimental systems with insufficient PLA2G6 activity might respond poorly to MOTS-c-based interventions, a consideration that could shape future strategies for patient selection.

Taken together, the study identifies a novel role for MOTS-c dysregulation in mediating vascular endothelial damage in diabetic retinopathy and proposes MOTS-c supplementation as a potential therapeutic approach, one that works by regulating phospholipid homeostasis and protecting the endothelial barrier through PLA2G6. The conceptual appeal is considerable. Rather than blocking a single growth factor after the vasculature has already begun to fail, a MOTS-c-based strategy would aim to reinforce the fundamental resilience of endothelial membranes early in the disease, when intervention could still prevent the cascade of leakage, inflammation and pathological vessel growth that ultimately destroys vision. It also adds to a growing appreciation that mitochondrial-derived peptides are not metabolic footnotes but active hormones with tissue-specific protective functions.

Substantial work remains before this biology reaches the clinic. The findings, published as an open-access article in Cell Death Discovery on 10 October 2026, were obtained in cell culture and in a mouse model of diabetes, and translating a mitochondrial peptide into a safe, durable therapy for human eyes will require solving questions of delivery, dosing, stability and long-term safety that the current study did not address. Human diabetic retinas, exposed to years of metabolic fluctuation, may behave differently from acute experimental hyperglycemia. Yet the study offers something the field has lacked: a defined molecular axis, running from a mitochondrial genome-encoded peptide through phospholipase A2 activity and lipid peroxide clearance to the integrity of the blood-retinal barrier. If that axis holds up in further preclinical and clinical testing, the smallest genome in our cells may turn out to hold one of the larger answers to diabetic blindness.

Subject of Research: The role of the mitochondrial-derived peptide MOTS-c and phospholipase A2 group VI in protecting retinal endothelial cells in diabetic retinopathy

Article Title: Mitochondrial-derived peptide MOTS-c rescues vascular endothelial damage via PLA2G6 in diabetic retinopathy

Article References: Liao, Y., Xiang, J., Xia, Y., Liu, C., He, C., Tong, J., Chen, Y., Yao, G., & Xie, Z. (2026). Mitochondrial-derived peptide MOTS-c rescues vascular endothelial damage via PLA2G6 in diabetic retinopathy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03384-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03384-5

Keywords: MOTS-c, mitochondrial-derived peptide, diabetic retinopathy, retinal endothelial cells, PLA2G6, phospholipase A2, lipid peroxides, endothelial barrier, mitochondrial dysfunction, phospholipid metabolism, blood-retinal barrier, diabetes complications